A review of treatment of pompe disease in infants

Biologics: Targets and Therapy

Volumn 1, Issue 3, 2007, Pages 195-201

  Chien, Yin Hsiu ^a   Hwu, Wuh Liang ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Alglucosidase alfa; Alpha glucosidase; Pompe disease

Indexed keywords

EID: 79956191593     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Amalfitano A, Bengur AR, Morse RP, et al. 2001. Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet Med, 3:132-8.
2. Ansong AK, Li JS, Nozik-Grayck E, et al. 2006. Electrocardiographic response to enzyme replacement therapy for Pompe disease. Genet Med, 8:297-301.
3. Barranger JA, O'Rourke E. 2001. Lessons learned from the development of enzyme therapy for Gaucher disease. J Inherit Metab Dis, 24 (Suppl 2):89-96; discussion 87-8.
4. Bashan N, Potashnik R, Barash V, et al. 1988. Glycogen storage disease type II in Israel. Israel J Med Sci, 24:224-7.
5. Beck M. 2002. Agalsidase alfa-a preparation for enzyme replacement therapy in Anderson-Fabry disease. Expert Opin Investig Drugs, 11:851-8.
6. Beck M. 2007. New therapeutic options for lysosomal storage disorders: enzyme replacement, small molecules and gene therapy. Hum Genet, 121:1-22.
7. Bembi B, Ciana G, Martini C, et al. 2003. Efficacy of multidisciplinary approach in the treatment of two cases of nonclassical infantile glyco- genosis type II. J Inherit Metab Dis, 26:675-81.
8. Bijvoet AG, Kroos MA, Pieper FR, et al. 1996. Expression of cDNA- encoded human acid alpha-glucosidase in milk of transgenic mice. Biochimica et biophysica acta, 1308:93-6.
9. Bijvoet AG, Kroos MA, Pieper FR, et al. 1998. Recombinant human acid alpha-glucosidase: high level production in mouse milk, biochemical characteristics, correction of enzyme deficiency in GSDII KO mice. Hum Mol Genet, 7:1815-24.
10. Bijvoet AG, Van Hirtum H, Kroos MA, et al. 1999. Human acid alpha- glucosidase from rabbit milk has therapeutic effect in mice with glycogen storage disease type II. Hum Mol Genet, 8:2145-53.
11. Boerkoel CF, Exelbert R, Nicastri C, et al. 1995. Leaky splicing mutation in the acid maltase gene is associated with delayed onset of glycogenosis type II. Am J Hum Genet, 56:887-97.
12. Brady RO. 2006. Enzyme replacement for lysosomal diseases. Annu Rev Med, 57:283-96.
13. Brady RO, Pentchev PG, Gal AE, et al. 1974. Replacement therapy for inherited enzyme deficiency. Use of purified glucocerebrosidase inGaucher's disease. N Engl J Med, 291:989-93.
14. Case LE, Hanna R, Frush DP, et al. 2007. Fractures in children with Pompe disease: a potentiallong-term complication. Pediatr Radiol, 37:437-45.
15. Chamoles NA, Blanco M, Gaggioli D. 2001. Diagnosis of alpha-L-iduronidase deficiency in dried blood spots on filter paper: the possibility of newborn diagnosis. Clin Chem, 47:780-1.
16. Chamoles NA, Blanco M, Gaggioli D, et al. 2002a. Gaucher and Niemann-Pick diseases-enzymatic diagnosis in dried blood spots on filter paper: retrospective diagnoses in newborn-screening cards. Clin Chim Acta, 317:191-7.
17. Chamoles NA, Blanco M, Gaggioli D, et al. 2002b. Tay-Sachs and Sandhoff diseases: enzymatic diagnosis in dried blood spots on filter paper: retrospec- tive diagnoses in newborn-screening cards. Clin Chim Acta, 318:133-7.
18. Chamoles NA, Niizawa G, Blanco M, et al. 2004. Glycogen storage disease type II: enzymatic screening in dried blood spots on filter paper. ClinChim Acta, 347:97-102.
19. Chien YH, Lee NC, Peng SF, et al. 2006. Brain development in infantile- onset Pompe disease treated by enzyme replacement therapy. Pediatr Res, 60:349-52.
20. Cook AL, Kishnani PS, Carboni MP, et al. 2006. Ambulatory electro- cardiogram analysis in infants treated with recombinant human acidalpha-glucosidase enzyme replacement therapy for Pompe disease. Genet Med, 8:313-17.
21. Danon MJ, Oh SJ, DiMauro S, et al. 1981. Lysosomal glycogen storage disease with normal acid maltase. Neurology, 31:51-7.
22. De Duve C. 1963. The lysosome. Sci Am, 208:64-72.
23. de Duve C. 2005. The lysosome turns fifty. Nat Cell Biol, 7:847-9.
24. Furbish FS, Blair HE, Shiloach J, et al. 1977. Enzyme replacement therapy in Gaucher's disease: large-scale purification of glucocer- ebrosidase suitable for human administration. Proc Nat Acad Sci USA, 74:3560-3.
25. Gambetti P, DiMauro S, Baker L. 1971. Nervous system in Pompe's disease. Ultrastructure and biochemistry. J Neuropathol Exp Neurol, 30:412-30.
26. Hermans MM, van Leenen D, Kroos MA, et al. 2004. Twenty-two novel mutations in the lysosomal alpha-glucosidase gene (GAA) underscore the genotype-phenotype correlation in glycogen storage disease type II. Hum Mutat, 23:47-56.
27. Hers HG. 1963. Alpha-Glucosidase deficiency in generalized glycogenstorage disease (Pompe's disease). Biochem J, 86:11-16.
28. Hirschhorn R, Reuser AJJ. 2001. Glycogen storage disease type II: acid alpha-glucosidase (acid maltase) deficiency. In: Schriver CR, Beaudet AL, Sly WS, Valle D eds. The Metabolic and Molecular Bases of Inherited Disease. McGraw-Hill, New York, p 3389-420.
29. Howell RR, Byrne B, Darras BT, et al. 2006. Diagnostic challenges for Pompe disease: an under-recognized cause of floppy baby syndrome. Genet Med, 8:289-96.
30. Huie ML, Hirschhorn R, Chen AS, et al. 1994. Mutation at the catalytic site (M519V) in glycogen storage disease type II (Pompe disease). Hum Mutat, 4:291-3.
31. Hunley TE, Corzo D, Dudek M, et al. 2004. Nephrotic syndrome com- plicating alpha-glucosidase replacement therapy for Pompe disease. Pediatrics, 114:e532-5.
32. Kikuchi T, Yang HW, Pennybacker M, et al. 1998. Clinical and metabolic correction of pompe disease by enzyme therapy in acid maltase-deficient quail. J Clin Investig, 101:827-33.
33. Kishnani PS, Corzo D, Nicolino M, et al. 2007. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology, 68:99-109.
34. Kishnani PS, Hwu WL, Mandel H, et al. 2006a. A retrospective, multina- tional, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr, 148:671-6.
35. Kishnani PS, Nicolino M, Voit T, et al. 2006b. Chinese hamster ovary cell- derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease. J Pediatr, 149:89-97.
36. Kishnani PS, Steiner RD, Bali D, et al. 2006c. Pompe disease diagnosis and management guideline. Genet Med, 8:267-88.
37. Klinge L, Straub V, Neudorf U, et al. 2005a. Safety and efficacy of recombi- nant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial. Neuromuscul Disord, 15:24-31.
38. Klinge L, Straub V, Neudorf U, et al. 2005b. Enzyme replacement therapy in classical infantile pompe disease: results of a ten-month follow-up study. Neuropediatrics, 36:6-11.
39. Ko TM, Hwu WL, Lin YW, et al. 1999. Molecular genetic study of Pompe disease in Chinese patients in Taiwan. Hum Mutat, 13:380-4.
40. Kroos MA, Van der Kraan M, Van Diggelen OP, et al. 1995. Glycogen storage disease type II: frequency of three common mutant alleles and their associated clinical phenotypes studied in 121 patients. J Med Genet, 32:836-37.
41. Li Y, Scott CR, Chamoles NA, et al. 2004. Direct multiplex assay of lysosomal enzymes in dried blood spots for newborn screening. Clin Chem, 50:1785-96.
42. Lin CY, Shieh JJ. 1996. Molecular study on the infantile form of Pompe disease in Chinese in Taiwan. Zhonghua Minguo xiao er ke yi xue hui za zhi [Journal], 37:115-21.
43. Marsden D. 2005. Infantile onset Pompe disease: a report of physician narratives from an epidemiologic study. Genet Med, 7:147-50.
44. Martiniuk F, Chen A, Mack A, et al. 1998. Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease. Am J Med Genet, 79:69-72.
45. Nishino I, Fu J, Tanji K, et al. 2000. Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease). Nature, 406:906-10.
46. Nishioka T, Tomatsu S, Gutierrez MA, et al. 2006. Enhancement of drug delivery to bone: characterization of human tissue-nonspecific alkaline phosphatase tagged with an acidic oligopeptide. Mol Genet Metab, 88:244-55.
47. Pompe J-C. 1932. Over idiopatische hypertrophie van het hart. Ned Tijdshr Geneeskd, 76:304.
48. Poorthuis BJ, Wevers RA, Kleijer WJ, et al. 1999. The frequency of lysoso- mal storage diseases in The Netherlands. Hum Genet, 105:151-6.
49. Raben N, Danon M, Gilbert AL, et al. 2003. Enzyme replacement therapy in the mouse model of Pompe disease. Molecular genetics and metabo- lism, 80:159-69.
50. Raben N, Plotz P, Byrne BJ. 2002. Acid alpha-glucosidase deficiency (glycogenosis type II, Pompe disease). Curr Mol Med, 2:145-66.
51. Rosenberg M, Kingma W, Fitzpatrick MA, et al. 1999. Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: induction of humoral tolerance in seroconverted patients after repeat administration. Blood, 93:2081-8.
52. Rosenbloom BE, Weinreb NJ, Zimran A, et al. 2005. Gaucher disease and cancer incidence: a study from the Gaucher Registry. Blood, 105:4569-72.
53. Sakurai I, Tosaka A, Mori Y, et al. 1974. Glycogenosis type II (Pompe). The fourth autopsy case in Japan. Acta Pathol Jpn, 24:829-46.
54. Schram AW, Brouwer-Kelder B, Donker-Koopman WE, et al. 1979. Use of immobilized antibodies in investigating acid alpha-glucosidase in urine in relation to Pompe's disease. Biochimica et biophysica acta, 567:370-83.
55. Shin YS. 2006. Glycogen storage disease: clinical, biochemical, and molecular heterogeneity. Semin Pediatr Neurol, 13:115-20.
56. Shin YS, Endres W, Unterreithmeier J, et al. 1985. Diagnosis of Pompe's disease using leukocyte preparations. Kinetic and immunological studies of 1,4-alpha-glucosidase in human fetal and adult tissues and cultured cells. Clin Chim Acta, 148:9-19.
57. Taniguchi N, Kato E, Yoshida H, et al. 1978. alpha-glucosidase activity in human leucocytes: choice of lymphocytes for the diagnosis of Pompe's disease and the carrier state. Clin Chim Acta, 89:293-9.
58. Thurberg BL, Lynch Maloney C, Vaccaro C, et al. 2006. Characterization of pre- and post-treatment pathology after enzyme replacement therapy for pompe disease. Lab Invest, 86:1208-20.
59. Tomatsu S, Montano AM, Gutierrez M, et al. 2007. Characterization and pharmacokinetic study of recombinant human N-acetylgalactosamine- 6-sulfate sulfatase. Mol Genet Metab, 91:69-78.
60. Tsujino S, Huie M, Kanazawa N, et al. 2000. Frequent mutations in Japanese patients with acid maltase deficiency. Neuromuscul Disord, 10:599-603.
61. Umapathysivam K, Hopwood JJ, Meikle PJ. 2001. Determination of acid alpha-glucosidase activity in blood spots as a diagnostic test for Pompe disease. Clin Chem, 47:1378-83.
62. Umapathysivam K, Hopwood JJ, Meikle PJ. 2005. Correlation of acid alpha-glucosidase and glycogen content in skin fibroblasts with age of onset in Pompe disease. Clin Chim Acta, 361:191-8.
63. Umapathysivam K, Whittle AM, Ranieri E, et al. 2000. Determination of acid alpha-glucosidase protein: evaluation as a screening marker for Pompe disease and other lysosomal storage disorders. Clin Chem, 46:1318-25.
64. van den Hout H, Reuser AJ, Vulto AG, et al. 2000. Recombinant human alpha-glucosidase from rabbit milk in Pompe patients. Lancet, 356:397-8.
65. van den Hout HM, Hop W, van Diggelen OP, et al. 2003. The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature. Pediatrics, 112:332-40.
66. Van den Hout JM, Kamphoven JH, Winkel LP, et al. 2004. Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics, 113:e448-57.
67. Van Hove JL, Yang HW, Oliver LM, et al. 1997. Purification of recom- binant human precursor acid alpha-glucosidase. Bioch Mol Biol Int, 43:613-23.
68. Van Hove JL, Yang HW, Wu JY, et al. 1996. High-level production of recombinant human lysosomal acid alpha-glucosidase in Chinese hamster ovary cells which targets to heart muscle and corrects glycogen accumulation in fibroblasts from patients with Pompe disease. Proc Nat Acad Sci USA, 93:65-70.
69. Wenk J, Hille A, von Figura K. 1991. Quantitation of Mr 46000 and Mr 300000 mannose 6-phosphate receptors in human cells and tissues. Biochem Int, 23:723-31.
70. Wilcox WR, Banikazemi M, Guffon N, et al. 2004. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet, 75:65-74.
71. Winkel LP, Van den Hout JM, Kamphoven JH, et al. 2004. Enzyme replace- ment therapy in late-onset Pompe's disease: a three-year follow-up. Ann Neurol, 55:495-502.
72. Yang HW, Kikuchi T, Hagiwara Y, et al. 1998. Recombinant human acid alpha-glucosidase corrects acid alpha-glucosidase-deficient human fibroblasts, quail fibroblasts, and quail myoblasts. Pediatr Res, 43:374-80.
73. Zhu Y, Li X, Kyazike J, et al. 2004. Conjugation of mannose 6-phosphate- containing oligosaccharides to acid alpha-glucosidase improves the clearance of glycogen in pompe mice. J Biol Chem, 279:50336-41.
74. Zhu Y, Li X, McVie-Wylie A, et al. 2005. Carbohydrate-remodelled acid alpha-glucosidase with higher affinity for the cation-independent man- nose 6-phosphate receptor. demonstrates improved delivery to muscles of Pompe mice. Biochem J, 389:619-28.